BROOKLYN PARK, Minn.--(BUSINESS WIRE)--The National Institutes of Health (NIH) has informed CHF Solutions, Inc. that the CARRESS-HF trial has begun enrolling patients. Sponsored by NIH’s National Heart, Lung, and Blood Institute and chosen out of 16 national submissions for studies in heart failure, this study will compare CHF Solutions’ unique Aquapheresis therapy with standard medical drug therapy in patients hospitalized with acute decompensated heart failure (ADHF) and cardiorenal syndrome.
